Next report date
Report period
Q4 2023
EPS estimate
2.32MXN
Revenue estimate
7.81 BMXN
16.30MXN
3.58 BMXN
32.40 BMXN
173.44 M
About ROHTO PHARMACEUTICAL CO
Sector
Industry
Headquarters
Osaka
Website
Employees (FY)
7.18 K
Founded
1899
ISIN
JP3982400008
FIGI
BBG0125K9Y73
Rohto Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products, cosmetics, and functional food items. Its products include eye drops, contact lens care, dermal medicines, skin care, internal medicines, cold remedies, test kits, and denture cleansers. Its operations are carried out through the following segments: Japan, America, Europe, Asia, and Others. The company was founded by Anmin Yamada on February 22, 1899 and is headquartered in Osaka, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4527/N is 320.18 MXN — it has decreased by 7.56% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange ROHTO PHARMACEUTICAL CO stocks are traded under the ticker 4527/N.
ROHTO PHARMACEUTICAL CO is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
4527/N stock is 8.17% volatile and has beta coefficient of 1.00. Check out the list of the most volatile stocks — is ROHTO PHARMACEUTICAL CO there?
4527/N earnings for the last quarter are 3.84 MXN per share, whereas the estimation was 3.39 MXN resulting in a 13.30% surprise. The estimated earnings for the next quarter are 5.01 MXN per share. See more details about ROHTO PHARMACEUTICAL CO earnings.
ROHTO PHARMACEUTICAL CO revenue for the last quarter amounts to 7.78 B MXN despite the estimated figure of 7.46 B MXN. In the next quarter revenue is expected to reach 8.84 B MXN.
Yes, you can track ROHTO PHARMACEUTICAL CO financials in yearly and quarterly reports right on TradingView.
4527/N net income for the last quarter is 1.15 B MXN, while the quarter before that showed 875.31 M MXN of net income which accounts for 31.51% change. Track more ROHTO PHARMACEUTICAL CO financial stats to get the full picture.
Today ROHTO PHARMACEUTICAL CO has the market capitalization of 75.09 B, it has increased by 0.12% over the last week.
ROHTO PHARMACEUTICAL CO dividend yield was 0.79% in 2022, and payout ratio reached 19.03%. The year before the numbers were 0.97% and 19.44% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 4527/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ROHTO PHARMACEUTICAL CO stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 30, 2024, the company has 7.18 K employees. See our rating of the largest employees — is ROHTO PHARMACEUTICAL CO on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ROHTO PHARMACEUTICAL CO technincal analysis shows the neutral today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ROHTO PHARMACEUTICAL CO stock shows the strong buy signal. See more of ROHTO PHARMACEUTICAL CO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ROHTO PHARMACEUTICAL CO future price: according to them, 4527/N price has a max estimate of 494.99 MXN and a min estimate of 370.70 MXN. Read a more detailed ROHTO PHARMACEUTICAL CO forecast: see what analysts think of ROHTO PHARMACEUTICAL CO and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ROHTO PHARMACEUTICAL CO EBITDA is 5.92 B MXN, and current EBITDA margin is 17.32%. See more stats in ROHTO PHARMACEUTICAL CO financial statements.